Madhav Dhodapkar, MBBS
Articles
Dr Dhodapkar on the Role of Linvoseltamab in Relapsed/Refractory Multiple Myeloma
October 30th 2023Madhav V. Dhodapkar, MBBS, discusses the advantages and disadvantages of bispecific antibodies and CAR T-cell therapy in patients with relapsed/refractory multiple myeloma, as well as the potential role for the bispecific antibody linvoseltamab in this treatment paradigm.
Read More
Dr Dhodapkar on the Use of Linvoseltamab in Relapsed/Refractory Multiple Myeloma
October 4th 2023Madhav V. Dhodapkar, MBBS, discusses efficacy and safety findings from the dose-expansion portion of the phase 2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory multiple myeloma.
Read More
Latest Updated Articles
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data
